Search Results

Terumo Aortic’s RelayPro Thoracic Stent Graft System Introduced Commercially in United States

September 16, 2021—Terumo Aortic announced the first commercial implants in the United States of its RelayPro thoracic stent graft system, which was recently approved by the FDA for treatment of patients with fusiform and saccular aneurysms and penetrating atherosclerotic ulcers in the descending thoracic aorta.

TriVascular Begins LIFE Postmarket Registry for Ovation Prime in Fast-Track Setting

October 27, 2014—TriVascular Technologies, Inc. announced the commencement of enrollment in the LIFE Study, a multicenter postmarket registry designed to evaluate the Ovation Prime abdominal stent graft system in the treatment of patients with abdominal aortic aneurysms (AAA) using a fast-track protocol for endovascular aneurysm repair (EVAR).

Endologix Completes Patient Enrollment in the Ovation LIFE Study

May 16, 2016—Endologix, Inc. announced the completion of patient enrollment in the LIFE study, a multicenter postmarket registry designed to evaluate the company’s Ovation abdominal stent graft platform when used in the treatment of patients with abdominal aortic aneurysms (AAAs) using a fast-track protocol for endovascular aneurysm repair (EVAR).  According to Endologix, the LIFE (Least Invasive Fast-Track EVAR) study is the first of its kind using a fast-track EVAR protocol, which includes bilateral percutaneous access enabled by the Ovation platform’s ultra-low-profile (14-F) design, avoidance of general anesthesia and intensive care unit (ICU) admission postprocedure, and next-day discharge.  The study enrolled 250 patients at 34 sites in the United States.

TriVascular's Clinical Studies of Ovation EVAR Device Reach Milestones

August 3, 2015—TriVascular Technologies, Inc. announced it reached milestones in two clinical trials of the company’s Ovation abdominal stent graft platform for endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms.

FDA Approves Terumo Aortic’s RelayPro Thoracic Stent Graft

August 6, 2021—Terumo Aortic announced it has received FDA approval of RelayPro, the company’s low-profile, next-generation thoracic stent graft device designed for use in thoracic endovascular aortic repair for patients with small access vessels.